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ARTICLE
Modulation of AMPA receptor surface diffusion
restores hippocampal plasticity and memory in
Huntington’s disease models
Hongyu Zhang1,2,3, Chunlei Zhang1,2, Jean Vincent1,2, Diana Zala 4,5, Caroline Benstaali6,7, Matthieu Sainlos1,2,
Dolors Grillo-Bosch 1,2, Sophie Daburon1,2, Françoise Coussen1,2, Yoon Cho8, Denis J. David 9,
Frederic Saudou 6,7,10, Yann Humeau1,2 & Daniel Choquet 1,2,11
Impaired hippocampal synaptic plasticity contributes to cognitive impairment in Huntington’s
disease (HD). However, the molecular basis of such synaptic plasticity defects is not fully
understood. Combining live-cell nanoparticle tracking and super-resolution imaging, we show
that AMPAR surface diffusion, a key player in synaptic plasticity, is disturbed in various
rodent models of HD. We demonstrate that defects in the brain-derived neurotrophic factor
(BDNF)–tyrosine receptor kinase B (TrkB) signaling pathway contribute to the deregulated
AMPAR trafﬁcking by reducing the interaction between transmembrane AMPA receptor
regulatory proteins (TARPs) and the PDZ-domain scaffold protein PSD95. The disturbed
AMPAR surface diffusion is rescued by the antidepressant drug tianeptine via the BDNF
signaling pathway. Tianeptine also restores the impaired LTP and hippocampus-dependent
memory in different HD mouse models. These ﬁndings unravel a mechanism underlying
hippocampal synaptic and memory dysfunction in HD, and highlight AMPAR surface diffusion
as a promising therapeutic target.
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Cognitive deﬁcits and psychiatric disturbance prior tomotor dysfunction have been widely documented in pre-clinical Huntington’s disease (HD) gene carriers1,2. These
manifestations have traditionally been attributed to degeneration
or death of corticostriatal neurons3. However, mounting evidence
points to the involvement of deﬁcits in hippocampal synaptic
plasticity. This is supported by the ﬁndings that hippocampal
long-term potentiation (LTP), a major form of synaptic plasticity
widely regarded as a molecular basis for learning and memory, is
greatly impaired in different categories of HD mouse models at
pre- or early-symptomatic stage4–7. Moreover, the abnormally
increased ability to support long-term depression has also been
reported in HD mice8. Consistently, behavioral studies reveal
deterioration of hippocampal-associated spatial memory in dis-
tinct HD murine models, primate model9, and patients10.
The molecular mechanisms underlying hippocampal synaptic
and memory dysfunctions are not well understood but the brain-
derived neurotrophic factor (BDNF) signaling pathway seems to
play an important role. BDNF is a potent, positive modulator of
LTP11. The downregulation of its protein production and the
imbalance between the expression of its TrkB receptor and the
pan-neurotrophin receptor p75 (P75NTR) have been implicated in
the hippocampal synaptic and memory defects in HD. Indeed,
administration of BDNF or P75NTR gene knockdown ameliorates
HD-associated synaptic and memory dysfunction6,12. However,
the signaling mechanisms mediating BDNF modulation of
synaptic plasticity and mechanism-based pharmacological treat-
ment strategies remain largely unexplored. This may have sig-
niﬁcant therapeutic implications as the application of exogenous
BDNF is not clinically practical due to its instability in the
bloodstream and its inability to cross the blood–brain barrier, and
genetic intervention on human subjects may carry ethical issues.
AMPA receptors (AMPARs) are the major excitatory neuro-
transmitter receptors. The regulated trafﬁcking of AMPARs to
and from the synapses is thought to be a key mechanism
underlying glutamatergic synaptic plasticity13–15. Animal studies
reveal that AMPAR trafﬁcking plays a pivotal role in experience-
driven synaptic plasticity and modiﬁcation of behavior16. In
particular, we recently established that AMPAR surface diffusion
is mandatory for expression of LTP17. Pathological conditions,
such as acute stress or stress hormones, alter AMPAR trafﬁcking
and memory encoding processes. Thus monitoring and manip-
ulating synaptic AMPAR trafﬁcking emerges as a useful tool to
study cognitive function and dysfunction in animal models.
Synaptic delivery of AMPAR involves intracellular trafﬁcking,
insertion to the plasma membrane by exocytosis, and lateral
diffusion at the neuronal surface14,17,18. For many years, endo-
cytosis/exocytosis have been considered to be the main routes for
exit and entry of receptors from and to postsynaptic sites,
respectively. However, our laboratory and others have established
in the past decade that receptor surface diffusion is a key step for
modifying receptor numbers at synapses13,17,19,20. We have
demonstrated that deregulated AMPAR surface diffusion pri-
marily contributes to the impaired LTP in stress/depression
models21. Most importantly, we found that AMPAR surface
diffusion can be pharmacologically modulated by the clinically
used antidepressant tianeptine (S 1574, [3-chloro-6-methyl-5, 5-
dioxo-6,11-dihydro-(c,f)-dibenzo-(1,2-thiazepine)-11-yl) amino]-
7 heptanoic acid), which restores impaired LTP in a stress/
depression model22. Impaired synaptic plasticity is a common
mechanism underlying both cognitive impairment and psychia-
tric disturbance such as anxiety and depression, the major early-
onset symptoms in HD1,2,23. Hence, we have examined whether
AMPAR surface diffusion is disturbed in HD models, how this is
linked with impaired BDNF signaling, and whether pharmaco-
logical modulation of AMPAR surface diffusion by tianeptine can
serve as a promising therapeutic strategy to improve synaptic and
memory dysfunction as well as anxiety/depression-like behavior
in HD.
Results
AMPAR surface diffusion is deregulated in ﬁve HD models.
AMPARs are heteromeric proteins composed of different com-
binations of GluA1, GluA2, GluA3, or GluA4 subunits.
GluA1–GluA2 di-heteromers are the most common combination
in adult neurons14. We thus investigated endogenous GluA2- and
GluA1-AMPAR surface diffusion separately using the single
nanoparticle tracking approach in which a quantum dot (QD) is
coupled to an antibody speciﬁc for the extracellular domain of the
endogenous GluA2 or GluA1 subunit (Fig. 1a)22. We initially
used rat primary hippocampal neuronal cultures co-transfected
with homer1c-GFP and exon1 mutant huntingtin, which contains
69 polyglutamine expansion (exon1-polyQ-HTT), with exon1
wild-type (WT) huntingtin with 17 polyglutamine (exon1-
wHTT) and empty vector as controls24. Compared to empty
vector and exon1-wHTT, expression of exon1-polyQ-HTT sig-
niﬁcantly increased the surface diffusion of GluA2- and GluA1-
AMPAR (Fig. 1c, d, top panel). We conﬁrmed the co-transfection
efﬁciency of green ﬂuorescent protein (GFP) and HTT fused with
hemagglutinin (HA) tag (ratio 1:4). All GFP-expressing cells were
successfully transfected with HTT as revealed by HA staining
(Supplementary Fig. 1a, 1b). We next used rat primary hippo-
campal neuronal cultures co-transfected with GFP and full-length
mutant huntingtin, which contains 75 polyglutamine expansion
(FL-polyQ-HTT), with FL WT huntingtin with 17 polyglutamine
(FL-wHTT) as controls. Compared to FL-wHTT-expressing cells,
GluA2- and GluA1-AMPAR surface mobility was signiﬁcantly
increased in FL-polyQ-HTT-expressing cells (Fig. 1e, f, top
panel). To avoid possible transfection artifacts, we next used
primary hippocampal neurons from R6/1 heterozygous trans-
genic mice, which overexpress the ﬁrst exon of human HTT with
115 polyQ and represent a fast model of HD. Similarly, an
increase in GluA2- and GluA1-AMPAR surface diffusion was
observed in neurons from R6/1 mice compared to WT littermate
controls (Fig. 1g, h, top panel). Furthermore, to circumvent
overexpression artifacts and to better mimic the genetic situation
in patients, we used neurons from homozygous HdhQ111/Q111
knock-in (KI) mouse, in which polyQ repeats are directly engi-
neered into the mouse HTT genomic locus and wHTT/polyQ-
HTT is expressed at endogenous levels. Consistently, neurons
from HdhQ111/Q111 KI mouse also displayed marked increase in
GluA2- and GluA1-AMPAR surface diffusion compared to WT
littermates (Fig. 1i, j, top panel). Finally, we used CAG140 het-
erozygous KI mice. Heterozygous mice are highly relevant to the
disease, as the majority of HD patients are heterozygous3. In line
with the above-mentioned ﬁndings, GluA2- and GluA1-AMPAR
surface diffusion was signiﬁcantly increased in CAG140 mice
compared to WT littermates (Fig. 1k, l, top panel). These changes
were partially due to a decreased fraction of immobile GluA2-
and GluA1-AMPAR (surface diffusion ≤0.01 µm2 s−1) (Fig. 1c–l,
bottom panels). Cumulative distributions of diffusion coefﬁcients
shift toward the right in all HD models, indicating an increased
GluA2- and GluA1 AMPAR surface diffusion.
AMPAR level and synaptogenesis are unaltered in HD models.
We next evaluated the surface and total GluA2 expression in
different HD models. No signiﬁcant difference was found in
surface and total GluA2 expression in FL-wHTT-/polyQ-HTT-
expressing neurons (Supplementary Fig. 1c–f) neither in R6/1
mouse models (Supplementary Fig. 1g–j). We further assessed the
synapse numbers and did not ﬁnd signiﬁcant difference between
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FL-wHTT and polyQ-HTT-expressing neurons (Supplementary
Fig. 1k, 1l). Altogether, these experiments indicate that dis-
turbance of AMPAR surface diffusion occurs independently of
AMPAR protein expression levels and synaptogenesis.
BDNF synthesis and transport are decreased in HD models.
BDNF is a prominent positive modulator of LTP11, which has
been proposed to induce the delivery of AMPARs to the synapse
under basal conditions25. However, it is not known whether and
how AMPAR surface diffusion is modulated by BDNF signaling
and whether it plays a role in HD pathogenesis. We thus asked
whether deﬁcient BDNF signaling could account for the aberrant
AMPAR surface diffusion in HD mouse models. We ﬁrst char-
acterized changes in the protein level of BDNF in HD mice.
Consistent with a previous report6, using enzyme-linked immu-
nosorbent assay (ELISA), we observed a signiﬁcant decrease in
the protein level of BDNF in the hippocampus of 10-week-old
male R6/1 and HdhQ111/Q111 mice compared to respective
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littermate controls (Fig. 2b). We next studied BDNF intracellular
transport in 3 complementary HD cellular models, as data on the
BDNF intracellular transport in the hippocampus of HD mice are
still lacking. Neurons expressing polyQ-HTT exhibited slower
anterograde and retrograde BDNF intracellular transport relative
to wHTT-expressing neurons (Fig. 2c, d). Similarly, R6/1 and
HdhQ111/Q111 mouse hippocampal neurons exhibited slower
transport compared to respective WT littermate controls (Fig. 2e,
f, respectively). Note that we observed a slower BDNF velocity in
neurites (Fig. 2d, e) as compared to axons in hippocampal neu-
rons (Fig. 2f), which is consistent with previous studies in cortical
neurons26,27. Altogether, these data suggested that reduced BDNF
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Fig. 2 BDNF synthesis and intracellular transport were impaired in various HD models. a Schematic diagram showing that BDNF is modulated at synthesis,
transport, and secretion levels. b Hippocampal BDNF protein level determined by ELISA in R6/1 and HdhQ111/Q111 mice; values are mean ± s.e.m (% of WT);
n= 21 and 14 mice for WT and R6/1; n= 6 and 9 mice for WT and HdhQ111/Q111, respectively. c Representative kymographs of intracellular transport of
BDNF-containing vesicles (white trajectories) in a neurite (50 μm from soma) over 75 s in wHTT- and polyQ-HTT-expressing rat hippocampal neurons.
The velocity of BDNF transport was reﬂected by the slope of trajectories (moving distance against time). d–f Anterograde and retrograde BDNF transport
velocity in all neurites of wHTT- and polyQ-HTT-expressing rat hippocampal neurons (d) and hippocampal neurons from R6/1 mouse line (e) and in the
axon of hippocampal neurons from HdhQ111/Q111 mouse line (f); values are median ± 95% c.i. (d, e) or mean ± s.e.m (f); n= 5569, 5656, 5227, and 5706
trajectories for anterograde and retrograde wHTT and polyQ-HTT, respectively; n= 1424, 1710, 1376, and 1487 trajectories for anterograde and retrograde
WT and R6/1, respectively; n= 236, 261, 194, and 256 trajectories for anterograde and retrograde WT and HdhQ111/Q111, respectively. Signiﬁcance was
determined by unpaired two-tailed Student’s t test (b, f) or two-tailed Mann–Whitney test (d, e); *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 1 Deregulated GluA2-and GluA1-AMPAR surface diffusion in ﬁve complementary HD cellular models. a Experimental scheme for endogenous GluA2-
and GluA1-AMPAR surface tracking using quantum dot (QD). b Typical GluA2-QD trajectories (magenta) in hippocampal neurons expressing vector,
exon1-wHTT, and exon1-polyQ-HTT, respectively. Lower panels represent enlarged GluA2-QD trajectories. Scale bars, 10 μm. c, e, g, i, k Top panels,
GluA2-AMPAR diffusion coefﬁcients (median ± 25–75% interquartile range (IQR)) in rat hippocampal neurons expressing vector, exon1-wHTT, and exon1-
polyQ-HTT; n= 844, 382, and 695 trajectories, respectively (c), in rat hippocampal neurons expressing FL-wHTT or FL-polyQ-HTT; n= 603 and 760
trajectories, respectively (e), in hippocampal neurons from R6/1 mice and WT littermate controls; n= 1885 and 1994 trajectories, respectively (g), in
hippocampal neurons from HdhQ111/Q111 mice and WT littermate controls; n= 1571 and 886 trajectories, respectively (i), and in hippocampal neurons from
CAG140 mice and WT littermate controls; n= 2939 and 5457 trajectories, respectively (k). d, f, h, j, l Top panels, GluA1-AMPAR diffusion coefﬁcients
(median ± 25–75% IQR) in rat hippocampal neurons expressing vector, exon1-wHTT, and exon1-polyQ-HTT; n= 9337, 8320, and 10905 trajectories,
respectively (d), in rat hippocampal neurons expressing FL-wHTT or FL-polyQ-HTT; n= 4331 and 6462 trajectories, respectively (f), in hippocampal
neurons from R6/1mice and WT littermate controls; n= 18565 and 14195 trajectories, respectively (h), in hippocampal neurons from HdhQ111/Q111 mice and
WT littermate controls; n= 5612 and 5844 trajectories, respectively (j), and in hippocampal neurons from CAG140 mice and WT littermate controls; n=
8569 and 9170 trajectories, respectively (l). Bottom panels, cumulative probability of GluA2 and GluA1 diffusion coefﬁcient of respective top panel. The
ﬁrst point of the probability corresponding to the fraction of immobile receptors with diffusion coefﬁcients ≤0.01 μm2 s−1 shown by arrows. Note that the
cumulative curve shifts toward right indicating an increased GluA2 and GluA1 surface diffusion. Data were from 6 to 12 cells from three separate
experiments. Signiﬁcance was determined by Kruskal–Wallis test followed by Dunn’s multiple comparison test (c, d) or two-tailed Mann–Whitney test
(e–l); ***P < 0.001
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protein production and impaired intracellular transport are
common features of different categories of HD models.
Impaired BDNF-TrkB signaling impacts AMPAR surface dif-
fusion. Next, we dissected the potential signaling mechanism by
which BDNF modulates AMPAR surface diffusion in HD models.
BDNF is known to bind to TrkB receptors, leading to the acti-
vation of CaMKII11, which is known to regulate AMPAR surface
diffusion via impacting the interaction between TARP-2 (star-
gazin) and PSD95 during plasticity28. Active CaMKII phos-
phorylated at threonine 286 (T286) is reported to be reduced in
the hippocampus of HdhQ111/Q111 mouse models12. We also
detected the decrease in CaMKII activity in a HD cellular model
by co-transfecting rat hippocampal neurons with FL-wHTT/FL-
polyQHTT and a ﬂuorescence resonance energy transfer (FRET)-
based CaMKIIα, named REACH-CaMKII. The amino and car-
boxy termini of REACH-CaMKII are labeled with the FRET pair
of monomeric enhanced GFP (mEGFP) and resonance energy-
accepting chromoprotein (REACh), a non-radiative yellow
ﬂuorescent protein variant29. The activation of REACh-CaMKII
associated with T286 phosphorylation changes the conformation
of CaMKIIα to the open state in which its kinase domain is
exposed, thereby decreasing FRET and increasing the ﬂuores-
cence lifetime of mEGFP (Supplementary Fig. 2a). Rat hippo-
campal neurons transfected with GFP-PSD95 alone were used as
negative control. GFP-PSD95-expressing cells displayed long
lifetime (≥2.4 ns) in both dendritic puncta and shaft indicating no
FRET. FL-wHTT- and FL-polyQ-HTT-expressing cells both
exhibited FRET revealed by shorter lifetime than GFP-PSD95-
expressing cells, indicating activated CaMKIIα. However, the
REACh-CaMKIIα lifetime in dendritic puncta (Supplementary
Fig. 2c) and shaft (Supplementary Fig. 2d) in FL-polyQ-HTT-
expressing cells are signiﬁcantly lower than in FL-wHTT-
expressing cells, indicating stronger FRET and thus weaker
CaMKIIα activity.
The CaMKII-induced AMPAR immobilization requires the
interaction between stargazin and PSD9522,28. We thus examined
whether stargazin–PSD95 interaction was weakened in different
HD models. We ﬁrst used co-immunoprecipitation (Co-IP) and
demonstrated that PSD95–stargazin interaction was impaired in
the brain tissue from HdhQ111/Q111 mice relative to WT
littermates (Fig. 3a, b, Supplementary Fig. 6a). We further
performed DUOLINK in situ proximity ligation assay (PLA),
which allows for endogenous detection of protein interactions at
the single molecule level, in hippocampal neurons co-transfected
with GFP and vector, wHTT, or polyQ-HTT. Consistently, we
found that the PSD95–stargazin interaction was also markedly
decreased in polyQ-HTT-expressing neurons compared with
vector and wHTT controls (Fig. 3c, d).
We reasoned that, if reduced CaMKII activity is responsible for
aberrant AMPAR surface trafﬁcking, then overexpression of
constitutively active CaMKII should be able to rescue the FL-
polyQ-HTT-induced increase in AMPAR surface diffusion. This
is indeed what we observed (Fig. 3e, f). We assumed that, if
reduced CaMKII activity results from impaired BDNF-TrkB
signaling pathway, then the application of exogenous BDNF
should have similar effect. As expected, the application of
exogenous BDNF similarly restored a lower GluA2-AMPAR
surface diffusion (Fig. 3g, green bar). Moreover, BDNF applica-
tion could also decrease the AMPAR surface mobility in WT
neurons (Supplementary Fig. 3). This rescue effect of BDNF
requires the activation of TrkB and CaMKII as this effect was
completely blocked by the addition of the BDNF scavenger TrkB-
Fc or CaMKII inhibitor kn93 (Fig. 3g, orange and red bars,
respectively). This indicates that BDNF-TrkB-CaMKII signaling
pathway plays a key role in stabilizing surface AMPARs. We next
examined the role of the interaction between stargazin and PSD95
in mediating BDNF’s effects on AMPAR surface diffusion by
expressing ΔC stargazin (ΔC Stg), in which the interaction
domain with PDZ-domain scaffold proteins was deleted. In ΔC-
Stg but not WT stargazin-expressing neurons, administration of
BDNF failed to reduce GluA2-AMPAR surface diffusion (Fig. 3h).
These data suggest that impaired BDNF-TrkB-CaMKII signaling
contributes to the disturbance of AMPAR surface diffusion,
possibly by reducing interaction between TARP family protein
and PDZ-domain scaffold proteins in the hippocampus of HD
models.
Tianeptine improves BDNF level and transport in HD models.
BDNF is not a good candidate for HD treatment due to its
instability and difﬁculties to cross the blood–brain barrier30–32.
An alternative approach, therefore, is to elevate endogenous
BDNF protein or trafﬁcking using other exogenous agents. Our
previous work showed that the antidepressant tianeptine mod-
ulates AMPAR surface diffusion and improved LTP in stress/
depression models22. It has also been reported that chronic tia-
neptine treatment increased BDNF protein level in various rodent
brain structures33,34. However, the effect of tianeptine on BDNF
intracellular trafﬁcking is not known and it is unclear whether
tianeptine modulates BDNF signaling in HD models. We thus
examined the effect of tianeptine on BDNF protein production as
well as intracellular trafﬁcking in different HD models. Hippo-
campal BDNF protein production was evaluated using ELISA and
western blot methods in R6/1 and HdhQ111/Q111 mice at
10–12 weeks of age. Because at this age, R6/1 and HdhQ111/Q111
mice were reported to show LTP defects and R6/1 mice gradually
develop cognitive deﬁcits4,6. We found that the reduced hippo-
campal BDNF protein levels in R6/1 (Fig. 4a–c, Supplementary
Fig. 6b) and in HdhQ111/Q111 mice (Fig. 4d) were both sig-
niﬁcantly improved by tianeptine administration (25 mg kg−1,
intraperitoneally (i.p.) daily for 4 days for R6/1 mice; and 10 mg
kg−1, once for HdhQ111/Q111 mice). Note that a single tianeptine
injection at 10 mg kg−1 was inefﬁcient for R6/1 mice (data not
shown), which may be due to the more severe phenotypes in this
mouse model35. We next examined tianeptine effect on BDNF
intracellular trafﬁcking in three different HD cellular models. The
application of tianeptine fully rescued the velocity of BDNF
anterograde and retrograde transport in polyQ-HTT-expressing
neurons (Fig. 4e, f) as well as in hippocampal neurons from R6/1
(Fig. 4g) and HdhQ111/Q111 mice (Fig. 4h). In addition, tianeptine
also augmented BDNF intracellular trafﬁcking in wHTT-
expressing neurons and in neurons from WT control for
HdhQ111/Q111 mice (Supplementary Fig. 4). These data suggest
that tianeptine regulates hippocampal BDNF signaling at least at
two levels, namely, BDNF protein production and intracellular
transport.
Tianeptine rescues BDNF and AMPAR trafﬁcking deﬁcits via
BDNF-TrkB pathway. To further clarify the functional
mechanism of tianeptine, we examined whether the tianeptine-
induced increase in BDNF intracellular trafﬁcking could be pre-
vented by a selective TrkB receptor inhibitor, Cyclotraxin-B (CB),
which is a small inhibitor peptide mimicking the reverse turn
structure of the variable region III that protrudes from the core of
BDNF36. Indeed, tianeptine (50 μM) induced improvement of
anterograde and retrograde BDNF intracellular transport was
fully blocked by pre-incubation with CB (1 μM) (Fig. 5a, b). This
suggested that tianeptine’s effect on BDNF intracellular trafﬁck-
ing is likely mediated through TrkB receptor. Since BDNF is not
the sole ligand for TrkB receptor, we then postulated that, if
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tianeptine inﬂuences BDNF intracellular trafﬁcking through
BDNF signaling rather than working in parallel, then addition of
exogenous BDNF should be able to occlude tianeptine’s effect.
Indeed, the administration of BDNF (100 ng ml−1) similarly
rescued the decreased BDNF intracellular trafﬁcking induced by
polyQ-HTT and the combination of BDNF and tianeptine did
not exhibit additive effect (Fig. 5c). These data indicate that tia-
neptine affects BDNF intracellular trafﬁcking possibly through
BDNF-TrkB signaling pathway. We next asked whether tia-
neptine is also able to restore AMPAR surface trafﬁc and whether
this effect is mediated by TrkB receptors. The application of
tianeptine signiﬁcantly slowed down AMPAR surface diffusion in
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polyQ-HTT-expressing neurons, an effect fully blocked by the
TrkB receptor inhibitor CB and TrkB-Fc (Fig. 5d, e). Collectively,
these data suggest that the tianeptine effect on BDNF intracellular
trafﬁcking and AMPAR surface diffusion is mediated by BDNF-
TrkB signaling pathway.
Tianeptine restores AMPAR dynamics after LTP induction.
The increased AMPAR surface diffusion in basal conditions in
HD models prompted us to ask whether this could potentially
lead to abnormal AMPAR surface stabilization during activity-
dependent synaptic plasticity, such as LTP. Indeed, on the one
hand, it has been shown that activity-dependent synaptic
potentiation is associated with immobilization and subsequent
accumulation of AMPARs at synapses and that AMPAR surface
diffusion is mandatory for LTP17. On the other hand, polyQ
expansion of HTT is associated with impaired LTP4–7. We thus
examined AMPAR surface diffusion before and after 3-min
chemical LTP (cLTP) stimuli37 (300 μM Glycine, 1 μM Picro-
toxin, without Mg2+) in rat hippocampal neurons overexpressing
FL-wHTT or FL-polyQ-HTT using a super-resolution imaging
method, universal point accumulation for imaging in nanoscale
topography (uPAINT)38. uPAINT is not only able to generate
super-resolved images but also provides dynamic information
with large statistics revealing localization-speciﬁc diffusion
properties of membrane biomolecules. Endogenous GluA2-
AMPARs were tracked with ATTO 647 labeled anti-
extracellular GluA2 antibody and sorted into two groups
according to their diffusion coefﬁcient (immobile, Log (D)= <
−2; mobile, Log (D) >−2). In FL-wHTT-expressing neurons, we
observed a decrease in the ratio of mobile to immobile AMPAR
after cLTP stimuli relative to basal condition (Pre-LTP), reﬂecting
an immobilization of surface AMPARs (Fig. 6a, b). In contrast,
the ratio of mobile to immobile AMPAR in FL-polyQ-HTT-
expressing neurons was not signiﬁcantly different before and after
LTP stimuli (Fig. 6c, d). The effect was fully rescued by the
application of tianeptine (10 µM) (Fig.6e, f). These data suggest
that AMPARs fail to stabilize at the neuronal surface after LTP
stimuli in HD models, which could explain, at least in part, the
defects in the potentiation of AMPAR-mediated synaptic trans-
mission in HD. The rescue effect of tianeptine prompted us to
further evaluate its beneﬁcial effects on LTP deﬁcits in ex vivo
conditions.
Tianeptine restores hippocampal LTP and memory in HD
models. BDNF-TrkB signaling and AMPAR surface diffusion are
critically involved in hippocampal plasticity and learning and
memory11,14,17. We thus asked whether tianeptine could rescue
the impaired hippocampal LTP and hippocampal-dependent
memory in three different mouse models of HD. Besides male
heterozygous R6/1 transgenic mice and homozygous HdhQ111/
Q111 KI mice, we employed a third mouse model, male CAG140
heterozygous KI mice, for behavior test. CAG140 KI mice carry
140 polyQ and thus have earlier onset of symptoms than
HdhQ111/Q111 KI mice. Only male HD mice were used through-
out the paper in order to eliminate the possible inﬂuence of
gender differences. The ﬁeld excitatory postsynaptic potentials
(fEPSPs) were recorded from mouse hippocampal CA1 region
following Schaffer collateral stimulation (Fig. 7a, b). R6/1 trans-
genic mice and HdhQ111/Q111 KI mice were used at the age of
10–12 weeks. R6/1 mice showed a decrease in LTP of fEPSP slope
compared to WT littermate controls, which was partially rescued
by chronic treatment with tianeptine at 25 mg kg−1 (i.p. daily for
8 weeks) (Fig. 7a) but not tianeptine at 10 mg kg−1 (i.p. daily for
8 weeks) (data not shown). This suggested a dose-dependent
effect of tianeptine. Very similar results were obtained in
HdhQ111/Q111 mice, in which LTP defects were normalized by a
single injection of tianeptine (10 mg kg−1) (Fig. 7b).
The restorative effect of tianeptine on LTP in HD mice raises
the question of whether it can also rescue HD-related
hippocampus-dependent cognitive impairments. In order to test
early therapeutic intervention, we started to administer saline/
tianeptine (10 mg kg−1, i.p. daily) to R6/1 and WT littermate
mice from 4 weeks of age, when the mice do not typically present
cognitive deﬁcits4. At 12 weeks of age, the mice were subjected to
open ﬁeld test, Y-maze, and contextual fear conditioning. The
latter two tasks are hippocampal-dependent memory tasks,
respectively, based on novelty attractiveness and associated
threat39. Vehicle-treated R6/1 mice spent much less time in the
novel arm than vehicle-treated WT mice, suggesting that R6/1
mice have impaired spatial working memory (Fig. 7c). Interest-
ingly, tianeptine administration improved Y-maze performance
of R6/1 mice but not that of WT mice. This improvement is not
due to a change in moving velocity, as vehicle- and tianeptine-
treated R6/1 mice had similar moving velocity in open ﬁeld
(Supplementary Fig. 5a). Contextual fear conditioning, assessed
by measuring the freezing behavior a mouse typically exhibits
when re-exposed to a context in which a mild foot shock was
beforehand delivered, reﬂects hippocampal-dependent memory40.
Vehicle-treated R6/1mice exhibited less freezing in the contextual
fear test compared to vehicle-treated WT littermates, indicating a
worse memory, which was rescued by tianeptine treatment
(Fig. 7d). Similar to the spatial working memory tested in Y-
maze, no beneﬁcial effect was observed in tianeptine-treated WT
mice. We thus propose that tianeptine speciﬁcally rescued the
hippocampal-dependent memory of R6/1 mice.
As HD mice also typically present an anxiety/depression-like
phenotype, we asked whether chronic tianeptine treatment would
Fig. 3 Impaired BDNF-TrkB signaling contributes to the deregulated AMPAR surface diffusion by disrupting stargazin–PSD95 interaction in HD models. a
Representative blots of co-immunoprecipitation (Co-IP) of PSD95 and stargazin complexes. b Quantiﬁed densitometry of PSD95–Stg interaction band,
which is expressed as percentage relative to WT; n= 4 for WT and HdhQ111/Q111 mice. c Representative images of PSD95–Stg interaction determined by
DUOLINK in situ Proximity Ligation Assay, the number of the magenta puncta indicates the strength of the interaction. Scale bar, 10 μm. d Quantiﬁcation of
PSD95–Stg interaction strength in different groups for PLA, n= 35, 33, and 28 cells for Vector, wHTT, and polyQ-HTT groups, respectively. e Typical
GluA2-QD trajectories (magenta) in hippocampal neurons co-expressing FL-wHTT/polyQ-HTT and GFP or FL-polyQ-HTT and CamKII-GFP, respectively.
Scale bar, 10 μm. f–h GluA2-AMPAR diffusion coefﬁcients in rat hippocampal neurons co-expressing FL-wHTT/polyQ-HTT and GFP or FL-polyQ-HTT and
CamKII-GFP; n= 656, 685, and 349 trajectories, respectively (f), in neurons co-expressing FL-polyQ-HTT and GFP and treated with Vehicle, BDNF, TrkB-
Fc plus BDNF, or kn93 plus BDNF; n= 1649, 1742, 480, and 1380 trajectories, respectively (g), and in vehicle- or BDNF-treated neurons co-expressing FL-
polyQ-HTT and GFP or GFP-fused wild-type stargazin (Wt-stg-GFP) or ΔC stg, in which the binding domain to PDZ-domain scaffold protein was deleted; n
= 495, 568, 376, 300, 573, and 498 trajectories, respectively (h). Diffusion coefﬁcients were shown as median ± 25–75% IQR; Values are mean ± s.e.m (b,
d); data are representative of a minimum of three independent experiments. Signiﬁcance was determined by one-sample t test (b), one-way ANOVA
followed by Tukey’s multiple comparison test (d), or Kruskal–Wallis test followed by Dunn’s multiple comparison test (f–h); *P < 0.05, ***P < 0.001, ns no
signiﬁcance
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correct the anxiety/depression-like phenotype in CAG140 hetero-
zygous KI mice. The anxiety/depression-like behavior of CAG140
mice was assessed using the elevated plus maze (EPM) paradigm
and novelty suppressed feeding (NSF) paradigm. Anxiety-like
phenotypes are characterized by decreased time spent in open
arms in EPM or an increase in latency to feed in NSF, which we
observed in 6-month-old CAG140 mice (data not shown). Here
we speciﬁcally investigated the early intervention therapy in HD
and treated CAG140 mice starting from 3 months of age, when
the anxiety/depression-like phenotype is not fully established
(compared to 6-month-old mice, data not shown) and tested at
4 months of age. We found that, in comparison to vehicle-treated
CAG140 mice, chronically tianeptine-treated CAG140 mice spent
signiﬁcantly more time in open arms in EPM (Fig. 7e), while their
locomotor activity revealed by ambulatory distance was not
signiﬁcantly affected (Supplementary Fig. 5b). The treatment also
markedly decreased the latency to feed in NSF (Fig. 7f) without
altering the home food consumption (Supplementary Fig. 5c). In
contrast, tianeptine did not signiﬁcantly alter the behavioral
phenotype of WT mice, suggesting that chronic tianeptine
B
D
N
F
 p
ro
te
in
 le
ve
l
(E
lis
a,
 %
 o
f v
eh
ic
le
)
R6/1
*
4 days
wHTT
vehicle
polyQ-HTT
vehicle
Distance (35 μm)
T
im
e 
(7
5 
s)
polyQ-HTT
tianeptine
0
50
100
150
200
Ve
hic
le
Ti
an
ep
tin
e
25
 m
g 
kg
–1
a e
55
15
B
D
N
F
 p
ro
te
in
 le
ve
l
(E
lis
a,
 %
 o
f v
eh
ic
le
)
0
50
100
150
200
**
1 day
R6/1
*
4 days
R6/1
4 days
Tianeptine
25 mg kg–1
Vehicle
0
40
80
B
D
N
F
 v
el
oc
ity
(a
ll 
ne
ur
ite
s,
 μ
m
 s
–1
)
Anterograde
0.0
1.0
2.0
3.0
B
D
N
F
 v
el
oc
ity
(a
ll 
ne
ur
ite
s,
 μ
m
 s
–1
)
Anterograde
B
D
N
F
 v
el
oc
ity
(a
xo
n,
 μ
m
 s
–1
)
Anterograde
** ***
R6/1
Retrograde
0.0
1.0
2.0
Retrograde
* **
Retrograde
*** ***
m
B
D
N
F
 p
ro
te
in
 le
ve
l
(W
B
, %
 o
f t
ub
ul
in
)
mBDNF
Tubulin
KDa ***
***
***
***
polyQ-HTT
Tianeptine
***
***
***
***
*** ***
0.8
0.0
0.4
0.8
0.0
0.4
0.8
0.0
0.4
0.8
0.0
0.4
wH
TT
-v
eh
icl
e
Ve
hic
le
10
 μM
50
 μM
polyQ-HTT
Tianeptine
wH
TT
-v
eh
icl
e
Ve
hic
le
10
 μM
50
 μM
W
T-
ve
hic
le
Ve
hic
le
Ti
an
ep
tin
e
25
 m
g 
kg
–1
W
T-
ve
hic
le
Ve
hic
le
Ti
an
ep
tin
e
10
 m
g 
kg
–1
Ve
hic
le
Ti
an
ep
tin
e
10
 μM
W
T-
ve
hic
le
Ve
hic
le
Ti
an
ep
tin
e
10
 μM
Ve
hic
le
Ti
an
ep
tin
e
50
 μM
R6/1
HdhQ111/Q111HdhQ111/Q111 HdhQ111/Q111
W
T-
ve
hic
le
Ve
hic
le
Ti
an
ep
tin
e
50
 μM
b f
c g
d h
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06675-3
8 NATURE COMMUNICATIONS |  (2018) 9:4272 | DOI: 10.1038/s41467-018-06675-3 | www.nature.com/naturecommunications
treatment also speciﬁcally improves the anxiety/depression-like
behavior in HD mice.
Discussion
AMPAR surface diffusion plays a key role in regulating AMPAR
synaptic content during glutamatergic synaptic
plasticity13,17,19,20. AMPARs constantly switch on the neuronal
surface between mobile and immobile states driven by thermal
agitation and reversible binding to stable elements such as scaf-
fold or cytoskeletal anchoring slots or extracellular anchors. Even
in synapses, AMPARs are not totally stable with around 50% of
them moving constantly by Brownian diffusion within the plasma
membrane, promoting continuous exchanges between synaptic
and extrasynaptic sites13. This process is highly regulated by
neuronal activity and other stimuli. The majority of AMPARs
incorporated into synapses during LTP is from surface diffusion
while exocytosed receptors likely serve to replenish the extra-
synaptic pool available for subsequent bouts of plasticity17,20.
This AMPAR redistribution followed by immobilization and
accumulation of AMPARs at synapses is the crucial step for the
enhanced synaptic transmission during synaptic
potentiation17,20,28,41. In the present study, we found that HD-
causing mutation leads to deregulated AMPAR surface diffusion
and that AMPARs fail to stabilize at the surface after cLTP stimuli
using complementary HD models including ectopic expression of
WT or polyQ–exon1 and of full-length HTT constructs con-
taining WT or polyQ repeats in rat primary neurons. To further
study the impact of polyQ expansion on AMPAR mobility, we
used neurons from R6/1 transgenic mice that express the ﬁrst
exon of human HTT with approximately 115 glutamines. These
mice, in contrast to the highly used R6/2 model, show reduced
symptoms and may represent a less severe form of the polyQ-
induced pathology42. Since this transgenic model is based on the
overexpression of exon1, we also investigated receptor mobility in
neurons from two other HD KI mouse models. We ﬁrst used
neurons from HdhQ111/Q111 KI mice that are generated on a CD1
background and express a chimeric human HTT exon1 sequence
with 111 repeats of CAG in the mouse HTT protein as described
previously43. We also conﬁrmed the defect in AMPAR mobility
using mouse neurons from HdhCAG140/+ heterozygous KI mice.
These mice are generated on a C57/BL6J background and express
human HTT exon1 sequence with 140 repeats of CAG as
described previously44. We chose to use neurons from
HdhCAG140/+ mice rather than BAC models of HD as they
recapitulate the genetic situation observed in HD patients
(endogenous expression and heterozygous status). In addition,
HdhQ111/Q111 and HdhCAG140/+ mice are derived from different
genetic constructs. Importantly, HdhQ111/Q111 and HdhCAG140/+
mice show mild phenotypes as compared to R6/1 mice, further
supporting the relevance of the results obtained on AMPAR
mobility.
Our ﬁndings open a new perspective into the molecular
mechanism underlying the impaired hippocampal synaptic plas-
ticity in HD. It is noteworthy that disturbed AMPAR trafﬁcking is
also proposed to be one of the ﬁrst manifestations of synaptic
dysfunction that underlies Alzheimer’s disease, which shares
many clinical and pathological similarities with HD, such as
early-onset cognitive deﬁciency before perceptible neuronal
degeneration. Together with our previous ﬁnding that deregu-
lated AMPAR surface diffusion underlies impaired LTP in stress/
depression models21, these lines of evidence indicate that dysre-
gulation of AMPAR surface diffusion may represent a common
molecular basis for the impaired hippocampal synaptic plasticity
and memory in various neuronal disorders.
It is generally accepted that BDNF via interaction with TrkB
receptors enhances synaptic transmission and plasticity in adult
synapses, while its binding to p75NTR has been demonstrated to
negatively modulate synaptic plasticity, spine–dendrite mor-
phology, and complexity11. Recent studies show that impaired
BDNF delivery, as well as the abnormally reduced expression of
TrkB receptor and enhanced p75NTR expression account for the
hippocampal synaptic and memory dysfunction12,45,46. The
phosphorylation of GluA1 on Ser-831 through activation of
protein kinase C and CaMKII via TrkB receptors has been pro-
posed to be responsible for AMPAR synaptic delivery11. How-
ever, other evidence indicates that GluA1 phosphorylation at Ser-
831 alters single-channel conductance rather than receptor
anchoring47. Here we provide the ﬁrst evidence in HD models
that administration of BDNF slows down the increased AMPAR
surface diffusion possibly via interaction between TARP and
PDZ-domain scaffold protein, which is downstream of TrkB-
CaMKII signaling pathway. It is possible that both processes, that
is, change in the single-channel conductance and receptor
anchoring (this study), occur in parallel and affect AMPAR sig-
naling. Interestingly, the reduced CaMKII activity reported in
HdhQ111/Q111 KI mice could be prevented by normalization of
p75NTR levels12. This effect could be attributable to the pre-
servation of TrkB signaling, as it has been shown that decreasing
p75NTR expression or blocking its coupling to the small GTPase
RhoA normalizes TrkB signaling, while upregulation of p75NTR
signaling through PTEN (phosphatase and tensin homolog
deleted on chromosome 10) results in impaired TrkB signaling46.
Thus impaired BDNF delivery and aberrant processing of BDNF
signal may converge on the TrkB-CaMKII signaling pathway,
Fig. 4 Tianeptine rescues BDNF protein level and transport in complementary HD models. a–c R6/1 mice were treated with vehicle (saline) or tianeptine
(25mg kg−1, i.p. daily) for 4 days. Hippocampal BDNF protein level was assessed using ELISA (a); n= 14 and 13 mice for vehicle- and tianeptine-treated
R6/1 group, respectively. Mature BDNF (mBDNF) and tubulin were analyzed by immunoblot (b); quantiﬁed densitometry of mBDNF was expressed as
percentage relative to tubulin (c); n= 9 and 7 mice for vehicle- and tianeptine-treated R6/1 group, respectively. d HdhQ111/Q111 mice received one injection
of saline or tianeptine (10mg kg−1, i.p.). Hippocampal BDNF protein level was evaluated using ELISA; n= 9 and 8 mice for vehicle- and tianeptine-treated
HdhQ111/Q111 group, respectively. e Representative kymographs of intracellular transport of BDNF-containing vesicles (white trajectories) in a neurite (35 μm
from soma) over 75 s in vehicle- or tianeptine-treated rat hippocampal neurons expressing wHTT or polyQ-HTT. f–h Anterograde and retrograde BDNF
transport velocity in all neurites of vehicle- or tianeptine-treated wHTT- and polyQ-HTT-expressing rat hippocampal neurons (f), of hippocampal neurons
from vehicle- or tianeptine-treated R6/1 mice and WT littermates (g), and in the axons of hippocampal neurons from vehicle- or tianeptine-treated
HdhQ111/Q111 and WT mice (h); n= 5569, 5656, 3339, 5737, 5227, 5706, 3190, and 5663 trajectories for anterograde and retrograde BDNF velocity in
wHTT-vehicle, polyQ-HTT-vehicle, and polyQ-HTT-tianeptine (10 and 50 μM) neurons, respectively; n= 1424, 1710, 1512, 1376, 1487, and 1238
trajectories for anterograde and retrograde velocity in WT-vehicle, R6/1-vehicle, and R6/1-tianeptine (50 μM) neurons, respectively; n= 236, 261, 432,
194, 256, and 357 trajectories for anterograde and retrograde velocity in WT-vehicle, HdhQ111/Q111 -vehicle, and HdhQ111/Q111 -tianeptine (10 μM) neurons,
respectively. Values are mean ± s.e.m (a, c, d, h) or median ± 95% c.i. (f, g). Data are from three independent experiments. Signiﬁcance was determined by
unpaired two-tailed Student’s t test (a, c, d), Kruskal–Wallis test followed by Dunn’s multiple comparison test (f, g), or one-way ANOVA followed by Tukey
multiple comparison test (h); *P < 0.05, **P < 0.01, ***P < 0.001
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06675-3 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:4272 | DOI: 10.1038/s41467-018-06675-3 | www.nature.com/naturecommunications 9
which impacts the interaction between TARP and PDZ-domain
containing scaffold proteins and thus affects AMPAR surface
diffusion.
However, the fact that the stargazin–PSD95 interaction is
dramatically impaired while the decrease in phosphorylated
CaMKII in HD models is modest12, indicates that additional
signaling pathways downstream or in parallel to BDNF signaling
may also contribute to the disruption of stargazin–PSD95 inter-
action and AMPAR surface trafﬁcking. An imbalance between
synaptic versus extrasynaptic N-methyl-D-aspartate–type
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Typical GluA2-QD trajectories (magenta) in polyQ-HTT-expressing rat hippocampal neurons, treated with vehicle, tianeptine (50 μM), CB (1 μM) plus
tianeptine (50 μM), or TrkB-Fc (1 μg ml−1) plus tianeptine (50 μM). Scale bar, 10 μm. e GluA2-AMPAR diffusion coefﬁcients in FL-polyQ-HTT-expressing
rat hippocampal neurons treated with vehicle, tianeptine (50 μM), CB (1 μM), plus tianeptine (50 μM), or TrkB-Fc (1 μg ml−1) plus tianeptine (50 μM); data
are shown as median ± 25–75% IQR; n= 601, 535, 708, and 556 trajectories for 4 groups, respectively. Data are representative of a minimum of three
independent experiments. Signiﬁcance was assessed by Kruskal–Wallis test followed by Dunn’s multiple comparison test (b, c, e); ***P < 0.001; ns not
signiﬁcant
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glutamate receptor (NMDAR) activity48 has been reported in
HD models. NMDAR is known to activate CaMKII,
phosphatidylinositol-3 kinase/Akt and the mitogen-activated
protein kinase (MAPK) and crosstalk with BDNF signaling
pathways. It is possible that multiple signaling pathways syner-
gistically regulate AMPAR surface trafﬁcking.
Although we speciﬁcally studied the role of stargazin–PSD95
interaction in regulating AMPAR surface diffusion in HD models,
other TARP family members may also be involved. TARP family
members (γ-2, γ-3, γ-4, and γ-8) share the binding motif (TTPV)
to PDZ-domain scaffold proteins. Notably, γ-8 is the most
abundant TARP in the hippocampus49. In addition to PSD95, the
C-tail of TARPs also enables its potential interaction with other
PDZ scaffold proteins, such as SAP97 and SAP102. However,
compared to PSD95, SAP97 and SAP102 have much less effect on
AMPAR excitatory postsynaptic current50. We thus propose that
the interaction between TARP and PSD95 may12 represent a
prominent target in regulating trapping and stabilization of dif-
fusing AMPARs on the postsynaptic membrane.
Tianeptine is a well-tolerated antidepressant primarily used in
the treatment of major depressive disorders51. It is structurally
similar to a tricyclic antidepressant (TCA) but has different
pharmacological properties than typical TCAs as it produces its
antidepressant effects likely through the alteration of glutamate
receptor activity22,51. Tianeptine alters glutamatergic transmis-
sion, increasing, for instance, the phosphorylation of
GluA1 subunits52 and activating CaMKII and protein kinase A
via the p38, p42/44 MAPK, and c-Jun N-terminal kinase path-
ways53. Through unknown mechanisms, tianeptine prevents
stress-induced dendritic atrophy, improves neurogenesis, reduces
apoptosis, and normalizes metabolite levels and hippocampal
volume51. In the present study, we show in complementary HD
models that tianeptine restored AMPAR surface diffusion, via
BDNF-TrKB signaling pathway, and rescued defective LTP and
hippocampal-dependent memory. Interestingly, the activation of
BDNF-TrkB signaling pathway is also required for the effect on
the depression-like behavior of some typical antidepressants, such
as ﬂuoxetine and imipramine54,55. The mechanisms underlying
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chronic tianeptine treatment may involve BDNF-induced neu-
rogenesis51; however, our ﬁnding that a single-dose administra-
tion of tianeptine is sufﬁcient to rescue aberrant LTP in HdhQ111/
Q111 KI mice points to additional mechanisms. Given the critical
role of AMPAR surface diffusion in hippocampal synaptic
plasticity, we argue that the beneﬁcial effects of tianeptine on the
impaired LTP and hippocampal-dependent memory stem, at least
in part, from its normalization of AMPAR surface diffusion.
Although tianeptine is also able to augment BDNF intracellular
trafﬁcking in WT controls (Supplementary Fig. 4) and
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immobilize AMPAR surface diffusion under basal conditions22, it
did not signiﬁcantly improve hippocampal-dependent memory in
WT mice, suggesting that the maintenance of a physiological
dynamic equilibrium is key to an effective treatment. The present
study also shows beneﬁcial effect of tianeptine on the anxiety/
depression-like behavior in CAG140 KI mouse model. Note that
cognitive dysfunction and psychiatric pathologies such as
depression, stress, and anxiety are typical features of HD, which
occur well before the onset of motor dysfunction, thus the use of
tianeptine may represent a promising early therapeutic strategy
for HD targeting both psychiatric and cognitive defects. More-
over, that tianeptine is a clinically used drug will facilitate clinical
trials.
In conclusion, we unravel AMPAR surface diffusion as a
potential novel therapeutic target for early intervention in HD
and propose a new therapeutic strategy for HD using the anti-
depressant tianeptine, which improves hippocampal synaptic and
memory deﬁcits as well as anxiety/depression-like behavior in
HD mice possibly through the modulation of BDNF signaling
and AMPAR surface diffusion.
Methods
Transgenic mice, primary neuronal cultures, and transfection. The hetero-
zygous male R6/1 mice (Jackson Laboratory, Bar Harbor, ME) were crossed with
female C57BL/6 mice (Charles River, Lyon). Homozygous HdhQ111/Q111 KI mice of
HD on CD1 background are generous gift from M.E. MacDonald56. The CAG140
are heterozygous mice with C57Bl6N/J background. The animals were housed with
food and water ad libitum under a 12 h light–dark cycle. All work involving ani-
mals was conducted according to the rules of ethics of the Committee of University
of Bordeaux and the Aquitaine (France, A50120127) and the Institutional Animal
Care and Use Committee (European Directive, 2010/63/EU for the protection of
laboratory animals, permissions # 92-256B, authorization ethical committee CEEA
26 2012_100). Polymerase chain reaction genotyping with DNA extracted from a
piece of tail was carried to identify mice genotype.
Primary cultures of hippocampal neurons were prepared following a previously
described method from (1) Sprague-Dawley rats at E18; (2) HdhQ111/Q111 KI mice
and WT littermates at P0 for AMPAR surface tracking and HdhQ111/Q111 KI mice
and WT mice at E15 for BDNF intracellular tracking; and (3) R6/1 mice and WT
littermates at P057,58. Cells were plated at a density of 200 × 103 cells for rat culture
and 450 × 103 cells for mice culture per 60 mm dish on poly-lysine pre-coated
cover slips. Cultures were maintained in serum-free neurobasal medium
(Invitrogen) and kept at 37 °C in 5% CO2 for 20 days in vitro (DIV) at maximum.
Cells were transfected with appropriate plasmids using Effectene (Qiagen).
Plasmids and chemical products. Homer 1C::GFP with CaMKII promoter was
generated by subcloning homer 1C cDNA into the eukaryotic expression vector
pcDNA3 (Invitrogen); EGFP was inserted at the N-terminus of the Homer 1C
sequence. Exon1 mutant huntingtin contains 69 polyglutamine expansion (exon1-
polyQ-HTT) and WT huntingtin with 17 polyglutamine (exon1-wHTT)24. Full-
length HTT plasmids encode full-length huntingtin with 17 polyQ (FL-wHTT) or
75Q (FL-polyQ-HTT). GFP fused 480-17Q, 480-68Q huntingtin plasmids encode
the ﬁrst 480 amino acids fragment of huntingtin with 17 (Nter-wHTT) or 68
glutamines (Nter-polyQ-HTT)59,60. Tianeptine was purchased from T & W group
and MedChemexpress CO., Ltd; BDNF from Sigma-Aldrich; TrkB-Fc from R&D
Systems; and kn93 from Tocris. Homemade CB and CB synthesized by Bio S&T
were used.
CB synthesis. CB was synthesized at a 0.05 mmol scale. Amino acids were
assembled by automated microwave solid phase peptide synthesis on a CEM
microwave–assisted Liberty-1 synthesizer following the standard coupling proto-
cols provided by the manufacturer. Methionine was replaced by Norleucine (λ), a
more stable isostere. Linear peptide was cleaved (TFA:H2O:EDT:TIS, 94:2.5:2.5:1)
and puriﬁed by high-performance liquid chromatography (HPLC). Disulﬁde bond
formation was carried out for 10 h in H20 in the presence of dimethyl sulfoxide
(5%) and ammonium acetate (0.05 M) at high dilution of the peptide (100 µM).
Solvent excess was removed and the peptide was puriﬁed by reversed-phase (RP)-
HPLC (YMC C18, ODS-A 5/120, 250 × 20 mm2, ultraviolet detection at 228 and
280 nm, using a standard gradient: 5% MeCN containing 0.1% TFA for 5 min
followed by a gradient from 10% to 40% over 40 min in dH2O containing 0.1%
triﬂuoroacetic acid (TFA) at a ﬂow rate of 12 ml min−1). Peptides were char-
acterized by analytic RP-HPLC and matrix-assisted light desorption/ionization.
Peptides were quantiﬁed by absorbance measurement at 280 nm, aliquoted, lyo-
philized, and stored at −80 °C until usage.
Single-particle tracking of AMPAR using QD. Rat primary hippocampal neurons
were co-transfected at DIV 10–11 with GFP/homer1c-GFP and wHTT/polyQ-
HTT at the ratio of 1:9 to ensure that the majority of GFP-transfected neurons were
transfected with HTT. Homer1c was used as a postsynaptic marker. Endogenous
GluA2 and GluA1 QD tracking was performed at DIV 11–12 as previously
described22. Neurons were ﬁrst incubated with mouse monoclonal antibody against
N-terminal extracellular domain GluA2 subunit (a kind gift from E. Gouaux,
Oregon Health and Science University, USA) (1:1000) or rabbit polyclonal anti-
body against N-terminal extracellular domain GluA1 subunit (PC246, Calbiochem)
(1:200) for 7 min, followed by incubation with QD 655 Goat F(ab’)2 anti-mouse
(Invitrogen, 1:10,000 to 1:20,000) or anti-Rabbit IgG (Invitrogen, 1:10,000 to
1:20,000) for 4 min. The speciﬁcity of the antibodies was controlled using hippo-
campal neuron culture from GluA2- or GluA1-knockout mice in our laboratory
(data not shown). Non-speciﬁc binding was blocked by 5% bovine serum albumin
(Sigma-Aldrich). QDs were detected by using a mercury lamp and appropriate
excitation/emission ﬁlters. Images were obtained with an interval of 50 ms and up
to 1000 consecutive frames. Signals were detected using a CCD camera (Quantem,
Roper Scientiﬁc). QDs were followed on randomly selected dendritic regions for up
to 20 min. QD recording sessions were processed with the MetaMorph software
(Molecular Devices, Sunnyvale, USA). The instantaneous diffusion coefﬁcient, D,
was calculated for each trajectory, from linear ﬁts of the ﬁrst 4 points of the mean-
square-displacement versus time function using MSD(t)= < r2 > (t)= 4Dt. The
two-dimensional trajectories of single molecules in the plane of focus were con-
structed by correlation analysis between consecutive images using a Vogel algo-
rithm. QD-based trajectories were considered synaptic if colocalized with Homer
1C dendritic clusters for at least ﬁve frames.
BDNF intracellular transport. Rat hippocampal neurons were co-transfected at
DIV 9–10 with GFP-fused 480-17Q (GFP::Nter-wHTT) or 480-68Q (GFP::Nter-
polyQ-HTT) and mCherry-BDNF at the ratio of 4:1 using Effectene (QIAGEN).
Live imaging was carried out at DIV 10–11. The movement of BDNF-containing
vesicles was tracked using video microscopy on an inverted Leica DMI 6000 Year
microscope (Leica Microsystems, Wetzlar, Germany) equipped with a HQ2 camera
(Photometrics, Tucson, USA). The objective HCX PL used was a CS APO ×63 NA
1.32 oil. The atmosphere was 37 °C incubator created with year box and air heating
system (Life Imaging Services, Basel, Switzerland). Acquisitions and calculation
were done on the MetaMorph software (Molecular Devices, Sunnyvale, USA). For
BDNF axonal trafﬁcking in hippocampal neurons of mouse HdhQ111/Q111 KI and
WT mice, hippocampal neurons at E15 were used. Microchambers, neuronal
transfection as well as videomicroscopy were previously described27. Brieﬂy, images
were collected in stream mode using a Micromax camera (Roper Scientiﬁc) with an
exposure time of 100–150 ms. Projections, animations, and analyses were generated
using the ImageJ software (http://rsb.info.nih.gov/ij/, NIH, USA). Maximal pro-
jection was performed to identify the vesicle paths, which in our system corre-
sponds to vesicle movements in axons. Kymographs and analyses were generated
with the KymoToolBox, a home-made plug-in27.
Super-resolution imaging of AMPAR surface diffusion. uPAINT was used. Rat
primary hippocampal neurons were co-transfected at DIV 4 with homer1c-GFP
and FL-wHTT/polyQ-HTT for 2 weeks. Homer1c was used as a postsynaptic
marker. Atto647-conjugated mouse monoclonal antibody against N-terminal
extracellular domain GluA2 subunit (a kind gift from E. Gouaux, Oregon Health
and Science University, USA) (1:5000–1:10,000) was used. The microscope was a
Nikon Ti Eclipse (Nikon France S.A.S., Champigny-sur-Marne, France) equipped
with a the Perfect Focus System (PFS) and a TIRF arm and using objective Apo
TIRF ×100 oil NA 1.49 and a sensitive Evolve EMCCD camera (Photometrics,
Tucson, USA). The diode lasers used were at 491 and 635 nm. This system is
equipped by a motorized stage Ti-S-ER. The 37 °C atmosphere was created with an
incubator box and an air heating system (Life Imaging Services, Basel, Switzerland).
This system was controlled by the MetaMorph software (Molecular Devices,
Sunnyvale, USA).
BDNF enzyme-linked immunosorbent assay. The BDNF concentration was
evaluated using the BDNF ELISA Kit (Millipore, Abnova) following the protocol
provided by the company.
Western blot. Western blot is performed as previously described22. Ten µg of
protein was loaded per lane and analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS–PAGE). Primary antibodies anti-BDNF
antibody (Santa Cruz Biotechnology, sc-546, 1:200) and anti-Tubulin antibody
(Sigma-Aldrich, T5168, 1:4000) were used.
Co-immunoprecipitation. For each experiment, one mouse brain of 5-week-old
littermate WT or HDH-Q111 were homogenized in 6 ml of homogenization buffer
(20 mM Hepes, 0.15 mM EDTA, 0.4 mM EGTA, 10 mM KCl, pH 7.5, cocktail of
protease inhibitors (aprotinin, leupeptin, pepstatin-A, MG132, and pefabloc, 10 µg/
ml) and centrifuged for 10 min at 860 × g. The supernatant was centrifuged for 30
min at 17,000 × g. The pellet was homogenized with 20 strokes in 15 ml of the same
buffer adjusted at 15% sucrose. The homogenate was centrifuged for 10 min at
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860 × g, in order to remove genomic DNA. The supernatant containing the
membranes was centrifuged again for 30 min at 17,000 × g. Brain membranes were
solubilized in a medium containing 20 mM Hepes, 1% Triton-X100, 150 mM NaCl,
0.15 mM EDTA, 4 mM EGTA (pH 7.5) and the antiprotease cocktail, with 20
dunces with a potter. Sample was centrifuged for 45 min at 17,000 × g. All steps
were performed at 4 °C. Protein concentration was evaluated with a BCA assay.
Triton-X100 supernatant (0.5 mg) was incubated with the anti-stargazin antibody
(AB-9876, Millipore, 1:150) for 1 h at 4 °C and then incubated overnight with 50 µl
of protein-A Sepharose at 4 °C. Resin was washed with 1 ml of loading buffer and
0.5 ml of the same buffer containing 500 mM NaCl. Beads were resuspended in
100 µl of gel loading buffer, run on 4–15% SDS-PAGE, and immunoblotted with
anti-stargazin (AB-9876, Millipore, 1:1000) and anti-PSD95 (Neuromab, 75-028,
1:1000) antibodies. Pictures and quantitative analysis of western blots were per-
formed using the Li-Cor apparatus (Odyssey scanner v3.0).
DUOLINK in situ PLA. PLA was performed to evaluate the interaction between
stargazin and PSD95 in situ using Duolink In Situ Detection Reagents (Sigma
DUO92013) following the following protocol: https://www.sigmaaldrich.com/
technical-documents/protocols/biology/duolink-ﬂuorescence-user-manual.html.
Antibodies were anti-stargazin (Millipore 07-577, 1:100) and anti-PSD95 (Thermo
Scientiﬁc MA1-046, 1:100).
Extracellular recording in hippocampal CA1 pyramidal neurons. Male hetero-
zygous R6/1 mice, HdhQ111/Q111 KI mice and respective WT littermates were used
for ex vivo extracellular recording. HdhQ111/Q111 KI mice (10–12 weeks of age)
received a single injection of tianeptine (i.p., 10 mg kg−1) with glucose as negative
control; R6/1 mice received chronic tianeptine treatment (25 mg kg−1, i.p. daily)
starting from 4 weeks of age until 12 weeks of age. As described previously22, a
hippocampal slice was transferred to a superfusing recording chamber with tem-
perature controlled at 33.5 °C and continuously perfused with oxygenated artiﬁcial
cerebrospinal ﬂuid (ACSF) using a peristaltic pump (Ismatec, Switzerland). A
teﬂon-coated tungsten bipolar stimulating electrode (Phymep, Paris, France) was
positioned in stratum radiatum, allowing the afferent Schaffer
collateral–commissural pathway from the CA3 area to the CA1 region to be sti-
mulated. The fEPSPs were recorded from stratum radiatum of CA1 area, using a
glass electrode (3–5MΩ) pulled from borosilicate glass tubing (Harvard Apparatus,
USA; 1.5 mm O.D x 1.17 mm I.D) and ﬁlled with ACSF. Pulses were delivered at
7.5 s by a stimulus isolator (Isoﬂex, AMPI, Jerusalem, Israel), with adjusting current
intensity to obtain 30–40% of the maximum fEPSP. A theta-burst stimulation
(TBS) protocol (4 pulses, respectively, delivered at 100 Hz, repeated 10 times, at an
interval of 200 ms) was delivered by Clampex10.4 (Molecular Devices, USA) and
the stimulus isolator to induce LTP. Recordings were made continually for >60
min, following the TBS. Data were recorded with a Multiclamp700B (Axon
Instruments, USA) and acquired with Clampex10.4. The slope of the fEPSP was
measured using the clampﬁt10.4 software, with all values normalized to a 5 min
baseline period; the values of potentiation during 50–60 min after TBS were
reported in the ﬁgures. The percentages of potentiation during the last 10 min of
each recordings were plotted in cumulative probability curves. We did not include
recordings in which the ﬁber volley changed >30% from the baseline value or the
global evolution. No difference in ﬁber volley time course was detected between the
compared groups. The recording was performed blindly in terms of mice genotype
and treatment.
Behavioral tests. Male R6/1 and WT littermate mice were used for behavioral
tests. At 4 weeks of age, littermate mice with mixed genotypes were housed (3–5
per cage) in polycarbonate standard cages (33 × 15 × 14 cm3) and randomly allo-
cated to vehicle or drug treatment groups. Simple randomization method was used
for allocating WT and R6/1 mice to vehicle or drug treatment groups. The sample
size was chosen based on previous experience and publications. Mice received daily
i.p. injection of 0.9% saline (vehicle) or tianeptine (10 mg kg−1) dissolved in 0.9%
saline until 12 weeks of age, when the animals were subjected to a battery of
behavioral tests. On day 1, all mice were subjected to open ﬁeld test; on day 2,
spatial memory was assessed in Y-maze. Following a week of rest, on day 9, a subset
of mice was further tested for contextual fear conditioning, which is performed
lastly in order to minimize confounding factors. All behavioral testing was carried
out in the light phase (light intensity: 45–50 lux). Before each behavioral test, mice
were individually housed in standard cages with sawdust, food, and water and left
undisturbed in the experimental room at least 30 min before testing began.
Behavioral tests were performed blindly concerning mice genotype and treatment.
Open ﬁeld. The apparatus constituted of a white square arena (42 × 42 × 20 cm3).
Each animal was placed in the center of the arena and allowed to explore for 20
min. Images tracked from a camera above the maze were analyzed with Ethovision
(version 9.1). The total distance traveled and the time spent moving were analyzed
as readouts of locomotor activity. The apparatus was cleaned by ethanol 70%
between mice.
Y-maze. Hippocampal-dependent spatial working memory was evaluated using Y-
maze. The apparatus consisted of three identical gray plastic arms (42 × 8 × 15 cm3)
and spaced at 120° of each other. The maze was located in the middle of a room
containing a variety of extramaze cues. A digital camera was mounted above the
maze transmitting the data to a PC running the Ethovision system. Mice were
assigned two arms (start and familiar arm) to which they were exposed during the
ﬁrst phase of the test (habituation phase). The remaining third arm blocked by a
gray plastic door constituted the novel arm during the second phase (testing
phase). Mice were placed at the end of the start arm and allowed to explore freely
both the start and the other unblocked arm for 5 min before being removed from
the maze and returned to the waiting cage. After 10 min in the waiting cage, the test
phase began. During this phase, the door was removed and all three arms were
unblocked; mice were placed at the end of the start arm and allowed to explore the
entire maze for 2 min. During the habituation and testing phase, video timer was
started once the mouse had left the start arm and entered the center, thus, two mice
which did not leave start arm during test phase were excluded from the analysis.
The apparatus was cleaned between the two phases in order to avoid olfactory cues.
Time spent in the novel arm in comparison to time in all three arms was used as
one readout for hippocampal-dependent spatial memory. Y-maze analysis was
carried out blindly with respect to genotype or treatment.
Contextual fear conditioning. Contextual fear conditioning provides a measure of
memory by assessing a memory for the association between mild foot shock and a
salient environmental cue. In the fear conditioning test, freezing behavior is deﬁned
as the complete lack of movement, which is a characteristic fear response in
rodents, providing a readout of hippocampal-dependent memory. Fear con-
ditioning was performed in a testing chamber with internal dimensions of 25 ×
25 × 25 cm3, which has transparent plastic walls each side and steel bars on the
ﬂoor. A camera mounted at one side recorded each session. The chamber was
located inside a larger, insulated, transparent plastic cabinet (67 × 53 × 55 cm3) that
provided protection from outside noise. The cabinet contained a ventilation fan
that was operated during the sessions. Mice were held outside the experimental
room in individual cages prior to testing. Training chambers were cleaned with
100% ethanol solution before and after each trial to avoid any olfactory cues. The
experiments ran over 2 consecutive days. On Day 1, mice were placed in the
conditioning chamber and 2 min 28 s later received one footstock (2 s, 0.3 mA).
Mice were removed from the chamber 30 s after the shock. On Day 2, they
returned to the same conditioning chamber for a 3-min period in the exact same
conditions as Day 1 but without electrical shock, to evaluate context-induced
freezing. Contextual fear conditioning experiment was carried out blindly with
respect to genotype or treatment.
Elevated plus maze (EPM). Male CAG 140 heterozygous KI mice received daily i.
p. injection of saline or tianeptine at 10 mg kg−1 at 12 weeks of age. No rando-
mization methods were used for allocating WT and CAG 140 mice to vehicle or
drug treatment groups. Behavioral tests were performed at 16 weeks of age
unblindly. Each animal, over a week, was successively tested in the EPM and NSF,
which represent different anxiety and depression behavior paradigms. Behavioral
tests were performed during the light phase between 0700 and 1900 hours. EPM
was performed as previously61. The maze is a plus-cross-shaped apparatus, with
two open arms and two arms closed by walls linked by a central platform 50 cm
above the ﬂoor. Mice were individually put in the center of the maze facing an open
arm and were allowed to explore the maze during 5 min. The time spent in and the
number of entries into the open arms were used as an anxiety index. Locomotion
was also measured to ensure any confounding effects. All parameters were mea-
sured using a videotracker (EPM3C, Bioseb, Vitrolles, France).
Novelty suppressed feeding (NSF). The NSF is a conﬂict test that elicits com-
peting motivations: the drive to eat and the fear of venturing into the center of a
brightly lit arena. The latency to begin to eat is used as an index of anxiety/
depression-like behavior, because classical anxiolytic drugs as well as chronic
antidepressants decrease this measure. The NSF test was carried out during a 15-
min period as previously described61. Brieﬂy, the testing apparatus consisted of a
plastic box (50 × 50 × 20 cm3), the ﬂoor of which was covered with approximately
2 cm of wooden bedding. Twenty-four hours prior to behavioral testing, all food
was removed from the home cage. At the time of testing, a single pellet of food
(regular chow) was placed on a white paper platform positioned in the center of the
box. Each animal was placed in a corner of the box, and a stopwatch was imme-
diately started. The latency to eat (deﬁned as the mouse sitting on its haunches and
biting the pellet with the use of forepaws) was timed. Immediately afterwards, the
animal was transferred to its home cage, and the amount of food consumed by the
mouse in the subsequent 5 min was measured, serving as a control for change in
appetite as a possible confounding factor.
Statistics. Statistical analysis was performed using Prism 7.04 (GraphPad, USA).
D’Agostino & Pearson normality test and Shapiro–Wilk normality test were used
to test normal distribution. For two-group comparison, F test was used to test
variance within each group; for multiple group comparison, Brown–Forsythe test
and Bartlett’s test were used. Datasets, which were not normally distributed or with
unequal population variances, were transformed by converting the values to their
logarithms or square roots to ﬁt Gaussian distribution or to equalize the standard
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deviations. Data values were shown as mean ± s.e.m. for normally distributed data;
median ± 95% conﬁdence interval (95% c.i.) or median ± interquartile range for
non-normally distributed data. Normally distributed datasets with equal popula-
tion variances were compared using paired or unpaired Student’s t test (for two-
group, one-factor comparison), one-way analysis of variance (ANOVA) test fol-
lowed by Tukey’s multiple comparison test (for multi-group, one-factor compar-
ison), or two-way ANOVA followed by Tukey’s multiple comparison test (for
multi-group, two-factor comparison). Non-normally distributed datasets were
tested by non-parametric Mann–Whitney test (for two-group, one-factor com-
parison) or Kruskal–Wallis test followed by Dunn’s multiple comparison test (for
multi-group, one-factor comparison). Cumulative probability curves were com-
pared using Mann–Whitney/Wilcoxon’s test. Statistical signiﬁcance was indicated
by P values: *P < 0.05, **P < 0.01, and ***P < 0.001.
Data availability
The authors declare that all the data supporting the ﬁndings of this study are available
from the authors on reasonable request.
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